Taurine with chemotherapy and immunotherapy for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding taurine to standard chemo-immunotherapy before surgery helps treat locally advanced gastric cancer. It may be an option for patients whose tumors are PD-L1 positive and can be fully removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with stage II or III gastric or gastroesophageal junction cancer that has not spread to other organs and can be surgically removed
- Your tumor tests positive for PD-L1 (CPS score of 1 or higher)
- You have not used taurine in the past month
- Your cancer does not have a HER2-positive result
- You do not have active bleeding, blockage, or perforation in your stomach or intestines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.